Full-Time

Certified Midwife Consultant

Confirmed live in the last 24 hours

IQVIA

IQVIA

10,001+ employees

Analytics and research for life sciences

Compensation Overview

$50 - $60/hr

Mid, Senior

Company Historically Provides H1B Sponsorship

Cambridge, MA, USA

Short-term assignment (2-3 weeks) with the possibility of extension; must be willing to commute to Cambridge, MA.

Category
Nursing & Allied Health Professionals
Medical, Clinical & Veterinary
Requirements
  • Certified Nurse Midwife (required)
  • Active and unrestricted RN License (required)
  • Willingness to work a short-term assignment (2-3 weeks)
  • Must be willing to commute to Cambridge, MA (required)
  • Current on all vaccinations as duties may require compliance with client and hospital expectations
Responsibilities
  • Communicate regularly with local, zone and management teams.
  • Exhibit superior technical, clinical, and presentation skills at all times
  • Professionally handle objections and questions
  • Participate in BU sponsored programs as requested (Clinical trials, validation programs, research events, education events, etc.)
  • Participate in Market Development activities as requested (Key Customer Programs, Image acquisition, etc.)
  • Build technical, clinical, and professional skills and knowledge (New registries, cross training, relevant business courses, personal development courses, etc.)
  • Submit weekly schedule to management
  • Maintain expenses according to company policy
  • Maintain company property
  • Act in a positive and professional manner at all times
  • Maintain current and compliant with CRM Tool guidelines
  • Meet the physical demands of the job including maneuvering of ultrasound equipment
Desired Qualifications
  • Experience in Obstetrics, Labor and Delivery and/or Maternal/Fetal Health (preferred)
  • 1+ year(s) Clinical experience (preferred)
  • Experience working Epic and Cerner (HCR) strongly preferred
  • Experience working with Excel is strongly preferred
  • Data entry experience is strongly preferred

IQVIA provides advanced analytics, technology solutions, and clinical research services specifically for the life sciences industry. Their main offering, IQVIA Connected Intelligence™, utilizes large datasets and technology to deliver quick insights that help clients speed up the development and marketing of new medical treatments. This service is designed to improve healthcare outcomes by connecting various aspects of healthcare. Unlike many competitors, IQVIA places a strong emphasis on patient privacy, using advanced technologies to protect individual data. The company's goal is to enhance understanding of diseases and human behavior, ultimately contributing to the development of cures.

Company Size

10,001+

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • IQVIA's Med-R1 8B LLM aids healthcare professionals in interpreting complex clinical data.
  • Winning the 2025 MedTech Breakthrough Award boosts IQVIA's reputation in patient engagement.
  • Recognition in IDC MarketScape's 2024 assessment highlights IQVIA's leadership in decentralized trials.

What critics are saying

  • Public scrutiny from Vimergy's campaign may impact IQVIA's reputation and client relations.
  • CAR T-cell therapy access disparities in Europe could lead to regulatory pressures on IQVIA.
  • $2 billion senior notes offering may increase financial risk if market conditions worsen.

What makes IQVIA unique

  • IQVIA leverages AI-powered analytics to enhance clinical research and healthcare solutions.
  • The company is a leader in protecting individual patient privacy with advanced technologies.
  • IQVIA's global presence spans over 100 countries, offering extensive domain expertise.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Life Insurance

Flexible Work Hours

Paid Vacation

Wellness Program

401(k) Retirement Plan

Company News

Business Wire
Jun 3rd, 2025
IQVIA Announces Pricing of Senior Notes

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of $2,000,000,000 in...

IQVIA
Jun 3rd, 2025
IQVIA announces offering of senior notes

<p> <strong>RESEARCH TRIANGLE PARK, N.C.</strong> &ndash; IQVIA Holdings Inc. (&ldquo;IQVIA&rdquo;) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the &ldquo;Issuer&rdquo;), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the &ldquo;Notes&rdquo;). </p> <p> The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer&rsquo;s revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate purposes. The consummation of the Notes offering is subject to market and other customary conditions. </p> <p> This press release does not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any offer, solicitation or sale of the Notes in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful. The Notes to be offered have not been registered under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. The Notes are being offered only to persons reasonably believed to be qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act and outside the United States only to non-U.S. investors pursuant to Regulation S under the Securities Act. Any offer of the Notes will be made only by means of a private offering memorandum. </p> <br /> <h5> About IQVIA </h5> <p> IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA&rsquo;s portfolio of solutions are powered by IQVIA Connected Intelligence&trade; to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI&trade;, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 89,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. </p> <p> IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA&rsquo;s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. </p> <br /> <h5> Forward Looking Statements </h5> <p> Certain statements in this press release are forward-looking statements. These statements involve a number of risks, uncertainties and other factors, including the failure to consummate the Notes offering, and potential changes in market conditions that could cause actual results to differ materially. </p> <br /> <h5> IQVIAFIN </h5> <p> Kerri Joseph, IQVIA Investor Relations (<a href="mailto:[email protected]">[email protected]</a>)<br /> +1.973-541-3558 </p>

IQVIA
Jun 1st, 2025
IQVIA Health Research Space wins 2025 Medtech Breakthrough Award for 'Best Mobile App for Patient Engagement'

Research Triangle Park, N.C., - June 16, 2025 - IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, has been selected as the winner of the "Best Mobile App for Patient Engagement" in the ninth-annual MedTech Breakthrough Awards program.

PR Newswire
May 19th, 2025
Vimergy Launches The "Mouth Of America" - Exposing A System That Profits When We Stay Sick

New National Campaign Confronts the Healthcare Industry's Perverse Incentives and Sparks a Movement for Preventive WellnessNEW YORK, May 19, 2025 /PRNewswire/ -- Vimergy, the premium supplement company helping people reclaim their health with pure, potent, and timeless products, today launched the "Mouth of America" – an immersive national campaign debuting a large-scale art installation in New York City. Designed to provoke and inspire, the campaign calls attention to America's real health crisis: chronic, system-driven illness fueled by a healthcare model that profits when we stay sick. This problem shows no sign of abating: In 2024, Americans collectively took 215 billion doses of prescription medication

PharmiWeb
Apr 24th, 2025
New Iqvia Institute Report Warns Of Access Disparities For Car T-Cell Therapy Across Europe

NEW IQVIA INSTITUTE REPORT WARNS OF ACCESS DISPARITIES FORCAR T-CELL THERAPY ACROSS EUROPEStockley Park, UK – 23 April 2025 – A new report reveals disparities in chimeric antigen receptor (CAR) T-cell therapy delivery across Europe, with healthcare system utilisation rates of the therapy as low as 11% for eligible patients. The independent research ‘Achieving CAR T-Cell Therapy Health System Readiness: An assessment of barriers and opportunities’ by the IQVIA Institute for Human Data Science, funded by Gilead and Kite, highlights challenges across countries that can lead to uneven access to CAR T-cell therapy. The report, which assessed seven countries (Australia, Canada, France, Germany, Italy, Spain, the United Kingdom), found that factors such as complex referral pathways, limited treatment centers and reimbursement challenges are hindering access to this potentially life-saving treatment for eligible patients."CAR T-cell therapy, a potentially curative treatment that has been available since 2017, has transformed the lives of thousands of people worldwide," says Murray Aitken, Executive Director, IQVIA Institute for Human Data Science. "Despite the progress, access barriers still remain for patients eligible for CAR T-cell therapy, leading to worrying inequities in care across Europe. The Institute’s report stresses the need for policy action to address these disparities, help people access this innovative treatment and improve patient outcomes."The IQVIA Institute shares key policy recommendations to support equitable patient access across healthcare systems. These include:1Establish standardised governance systems to coordinate care between referring and treating centres: Patient referrals continue to be a major challenge across countries, with 61% of referring physicians in Spain citing this as a main barrier to treatment.Develop plans to regularly monitor progress and timely access to CAR T-cell therapy: Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%.Long-term assessment and monitoring are required to address low utilisation rates across countries, with France delivering the highest percentage of eligible patients receiving treatment at only 30%